#Hagens Berman #Regeneron #class actions

Regeneron Pharmaceuticals Faces Class Action Lawsuit

An alarming situation has emerged for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) as it finds itself at the center of a class action lawsuit. The legal turmoil comes in the wake of shocking revelations pertaining to a Phase 3 clinical trial intended for treating melanoma patients, leading to widespread financial losses among investors.

Overview of the Situation

On July 29, 2026, the company reported that the recent clinical trial aimed at evaluating the efficacy of a treatment combining Fianlimab and Libtayo produced disappointing results. The failure of this trial had catastrophic effects on Regeneron's share prices, resulting in an astonishing market cap loss of around $11 billion. Consequently, this unexpected downturn has led to a lawsuit that seeks to represent investors who acquired Regeneron's common stock during the period from August 1, 2025 to May 15, 2026.

National shareholder rights firm Hagens Berman is spearheading an investigation concerning the legal claims and has urged those investors with significant financial losses to act swiftly. They have also expressed an open invitation for individuals who can provide additional information to assist in their investigation.

Allegations Against Regeneron

The crux of the lawsuit revolves around claims that Regeneron provided misleading statements regarding the Phase 3 trial results. Initially characterized as having